APO RESEARCH · REPORT
Hemophilia Gene Therapy
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Product & engineering
Understand the product.
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Selected research
Industry Growth & Trends
Global Hemophilia Gene Therapy Industry Growth and Trends Forecast to 2032
Market perspective
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
According to APO Research, the global Hemophilia Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Hemophilia Gene Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Hemophilia Gene Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hemophilia Gene Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hemophilia Gene Therapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Hemophilia Gene Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Hemophilia Gene Therapy Market by Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Hemophilia Gene Therapy Segment by Type
Hemophilia A
Hemophilia B
Hemophilia Gene Therapy Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
Hemophilia Gene Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hemophilia Gene Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Hemophilia A
- Hemophilia B
Applications
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
Companies covered
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Hemophilia Gene Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Hemophilia Gene Therapy Market Size by Region (2021-2032)
- 1.4.1 Global Hemophilia Gene Therapy Market Size by Region (2021-2026)
- 1.4.2 Global Hemophilia Gene Therapy Market Size by Region (2027-2032)
- 1.5 Key Regions Hemophilia Gene Therapy Market Size (2021-2032)
- 1.5.1 North America Hemophilia Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Hemophilia Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Hemophilia Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (2021-2032)
2 Hemophilia Gene Therapy Market by Type
- 2.1 Type Introduction
- 2.1.1 Hemophilia A
- 2.1.2 Hemophilia B
- 2.2 Global Hemophilia Gene Therapy Market Size by Type
- 2.2.1 Global Hemophilia Gene Therapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Hemophilia Gene Therapy Market Size by Regions
- 2.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Hemophilia Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Type (2021-2026)
3 Hemophilia Gene Therapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Hemophilia A Gene Therapy
- 3.1.2 Hemophilia B Gene Therapy
- 3.2 Global Hemophilia Gene Therapy Market Size by Application
- 3.2.1 Global Hemophilia Gene Therapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Hemophilia Gene Therapy Market Size by Regions
- 3.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Hemophilia Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Hemophilia Gene Therapy Industry Trends
- 4.2 Hemophilia Gene Therapy Industry Drivers
- 4.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
- 4.4 Hemophilia Gene Therapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Hemophilia Gene Therapy Revenue (2021-2026)
- 5.2 Global Hemophilia Gene Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Hemophilia Gene Therapy Key Company Headquarters & Area Served
- 5.4 Global Hemophilia Gene Therapy Company, Product Type & Application
- 5.5 Global Hemophilia Gene Therapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2025
- 5.6.3 2025 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Spark Therapeutics
- 6.1.1 Spark Therapeutics Company Information
- 6.1.2 Spark Therapeutics Business Overview
- 6.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
- 6.1.5 Spark Therapeutics Recent Developments
- 6.2 Ultragenyx
- 6.2.1 Ultragenyx Company Information
- 6.2.2 Ultragenyx Business Overview
- 6.2.3 Ultragenyx Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
- 6.2.5 Ultragenyx Recent Developments
- 6.3 Shire PLC
- 6.3.1 Shire PLC Company Information
- 6.3.2 Shire PLC Business Overview
- 6.3.3 Shire PLC Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
- 6.3.5 Shire PLC Recent Developments
- 6.4 Sangamo Therapeutics
- 6.4.1 Sangamo Therapeutics Company Information
- 6.4.2 Sangamo Therapeutics Business Overview
- 6.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
- 6.4.5 Sangamo Therapeutics Recent Developments
- 6.5 Bioverativ
- 6.5.1 Bioverativ Company Information
- 6.5.2 Bioverativ Business Overview
- 6.5.3 Bioverativ Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
- 6.5.5 Bioverativ Recent Developments
- 6.6 BioMarin
- 6.6.1 BioMarin Company Information
- 6.6.2 BioMarin Business Overview
- 6.6.3 BioMarin Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
- 6.6.5 BioMarin Recent Developments
- 6.7 uniQure
- 6.7.1 uniQure Company Information
- 6.7.2 uniQure Business Overview
- 6.7.3 uniQure Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
- 6.7.5 uniQure Recent Developments
- 6.8 Freeline Therapeutics
- 6.8.1 Freeline Therapeutics Company Information
- 6.8.2 Freeline Therapeutics Business Overview
- 6.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
- 6.8.5 Freeline Therapeutics Recent Developments
7 North America
- 7.1 North America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 7.3 North America Hemophilia Gene Therapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 8.3 Europe Hemophilia Gene Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Hemophilia Gene Therapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 10.3 South America Hemophilia Gene Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Hemophilia Gene Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst